JPMorgan analyst James Gordon lowered the firm’s price target on Genmab (GMAB) to DKK 1,700 from DKK 2,050 and keeps a Neutral rating on the shares.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter